Anti-CEA-CAR-T-cell-therapy-TNK-Therapeutics

Drug Profile

Anti-CEA-CAR-T-cell-therapy-TNK-Therapeutics

Alternative Names: Anti-CEA CAR-T; Anti-CEA T-cells; CAR-T CEA; CAR-T-CEA-therapy; CEA CART; Designer T-cells

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BDL Products, Inc.; CARgenix Holdings LLC
  • Developer Roger Williams Medical Center
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Carcinoembryonic antigen inhibitors; Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Liver metastases

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Liver metastases(Inoperable/Unresectable, Second-line therapy or greater) in USA (Intrahepatic, Infusion)
  • 03 Apr 2017 Safety and efficacy results from the phase I HITM-SIR clinical trial in Liver metastases released by Sorrento Therapeutics
  • 03 Apr 2017 TNK Therapeutics in collaboration with Roger Williams Cancer Center plans a phase II trial for Liver metastases in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top